Market disruptor about to take off

Posted 3 October 2024 AM

A deal struck by CSL Seqirus earlier this year could turn to gold if the TGA follows in the footsteps of its overseas counterparts which have approved the first needle-free epinephrine nasal spray, which is poised to significantly impact the treatment of life-threatening allergic reactions and disrupt the market, according to analysts.

CSL Seqirus signed a deal with San Diego-based ARS Pharma for Neffy in May which handed the Aussie giant rights to seek regulatory approval, reimbursement and commercialisation of the drug in Australia and New Zealand. ARS will remain responsible for manufacturing and supply.

To see the whole article, please login